The year is nearing its end, and now is a good opportunity to look at what happened throughout the 2012 to the stocks you follow. If you know the important things a company achieved, as well as any challenges it failed to overcome, then you can make a better decision about whether it really deserves a spot in your portfolio.
Today, I'll look at Merck , a member of the Dow Jones Industrials . The pharma giant has faced a lot of uncertainty due to the patent expiration of some of its best-selling drugs. But throughout the year, the stock has performed quite well. Below, you'll find more on what moved shares of Merck in 2012.
Stats on Merck
Year-to-Sate Stock Return
Total Revenue, Trailing 12 Months
Net Income, Trailing 12 Months
1-Year Revenue Growth
1-Year Normalized Earnings Growth*
CAPS Rating (out of five)
Source: S&P Capital IQ. *Adjusted to exclude unusual items.
Why has Merck taken off in 2012?
Merck has faced a pretty dramatic patent cliff recently. Just this year, sales of two of its leading drugs, Singulair and Remicade, tumbled as patent protection ended. Singulair, having just gone off-patent near mid-year, has already shown marked declines.
But the drugmaker has found success elsewhere. Diabetes drugs Januvia and Janumet have seen greatly increased sales. Moreover, the company has a strong stable of pipeline drugs in development, ranging from cancer-fighter vintafolide -- now in Phase 3 trials -- to osteoporosis drug odanacatib. In particular, the insomnia treatment suvorexant has done well in Phase 3 trials and could potentially crush competing products from Sanofi and Pfizer .
Still, Merck faces some risks in its existing drug line. Teva Pharmaceutical and Impax Laboratories have sued Merck to try to invalidate patents on its strong-selling Vytorin and Zetia drugs. If the suits succeed, then Merck may face an earlier-than-expected loss of revenue from these blockbusters.
Merck's great performance in 2012 owes to investor optimism that it can weather its patent cliff. If the company keeps executing well, then 2013 could be equally fruitful for shareholders.
If you want to know everything you can about Merck, don't stop here. Read our in-depth research report on the pharma giant to find out whether Merck's worth buying after its big run-up. Senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.
Click here to add Merck to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.
The article How Merck Beat Its Patent Cliff originally appeared on Fool.com.
Fool contributor Dan Caplinger has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.